Blog

Numinus Wellness Announces Voting Results From its Annual General Meeting of Shareholders

Jun 3 • 2 min read

VANCOUVER, BC, May 31, 2024 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is pleased to announce the voting results from its annual general meeting of shareholders (the “Meeting“), held earlier today. A total of…

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

May 31 • 2 min read

NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team will participate in the Jefferies Global Healthcare Conference being held from June 4-6, 2024. Details of the company’s participation:…

FSD Pharma Triumphs in Legal Dispute Against Former CEO Dr. Raza Bokhari

May 31 • 3 min read

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) has emerged victorious in its prolonged legal battle with the company’s former CEO, Dr. Raza Bokhari. Following years of litigation and an intensive eight-day evidentiary hearing, an arbitrator ruled against Bokhari, granting FSD Pharma three awards, including damages and compensation for the company’s arbitration-related fees and costs. On…

FTC’s Final Rule Amendment to the Health Breach Notification Rule and Its Implications

May 31 • 5 min read

On April 26, 2024, the Federal Trade Commission (FTC) issued a significant final rule amending its Health Breach Notification Rule (HBN Rule). This amendment aims to address the evolving landscape of personal health records (PHRs) and related technologies that fall outside the regulatory scope of the Health Insurance Portability and Accountability Act of 1996 (HIPAA)….

Optimi Health Announces Closing of Fully Subscribed $1,500,000 Financing

May 31 • 3 min read

VANCOUVER, BC, May 31, 2024 /CNW/ – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada-licensed GMP psychedelics pharmaceutical manufacturer specializing in controlled substances such as botanical psilocybin and MDMA, is pleased to announce it has closed a third and final tranche of its non-brokered private placement (the “Offering“). The Offering consisted of units (each a…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538